MARKET

CRTX

CRTX

Cortexyme
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.74
+0.90
+2.20%
Closed 16:42 08/05 EDT
OPEN
41.49
PREV CLOSE
40.84
HIGH
41.74
LOW
40.20
VOLUME
42.76K
TURNOVER
--
52 WEEK HIGH
73.84
52 WEEK LOW
19.35
MARKET CAP
1.23B
P/E (TTM)
-24.1272
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CRTX stock price target is 78.14 with a high estimate of 179.00 and a low estimate of 14.00.

EPS

CRTX News

More
Bristol Myers Squibb NDA, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha · 07/30 04:00
Cortexyme presents data showing potential of lead drug in CV disease and Alzheimer's
Cortexyme (CRTX -0.5%) announces encouraging preclinical data on lead candidate atuzaginstat (COR388) that, it says, support its potential for treating car
seekingalpha · 07/29 19:18
Cortexyme to Participate in Virtual Fireside Chat Hosted by LifeSci Capital on July 30, 2020
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced Stephen Dominy, M.D., the company’s chief scientific officer and co-founder, will part
Business Wire · 07/29 12:00
Cortexyme Presents Data Linking P. gingivalis Infection to Cardiovascular Disease Severity and Alzheimer's Disease, Along With Evidence That Treatment With Atuzaginstat (COR388) Improves Biomarkers Associated With Both Diseases
Cortexyme, a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases, today announced new preclinical data demonstrating the role of the bac
Business Wire · 07/28 22:09
Stocks To Watch: Big Focus On Big Tech
Seeking Alpha · 07/25 12:26
Cortexyme Announces Upcoming Data Presentations At The Alzheimer's Association International Conference 2020
Benzinga · 07/22 12:08
Cortexyme Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2020
Cortexyme, Inc. (Nasdaq: CRTX) today announced that its work to pioneer upstream therapeutic approaches to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases will be the subject of three research abstracts at the Alzheimer
Business Wire · 07/22 12:00
HC Wainwright & Co. Initiates Coverage On Cortexyme with Buy Rating, Announces Price Target of $76
HC Wainwright & Co. analyst Andrew Fein initiates coverage on Cortexyme (NASDAQ:CRTX) with a Buy rating and announces Price Target of $76.
Benzinga · 06/24 10:23

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About CRTX

Cortexyme, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The Company is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.
More

Webull offers kinds of Cortexyme Inc stock information, including NASDAQ:CRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRTX stock methods without spending real money on the virtual paper trading platform.